NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a credentialing agreement with managed care firm Prime Health Services to cover Rosetta's miRview mets2 test.

The deal is the first between Rosetta and a US preferred provider organization, Rosetta said. As a result, the number of covered lives having access to miRview mets2 as an in-network service totals more than 6.5 million.

The miRview mets2 assay is a microRNA-based assay for identifying the tumor of origin in cancers of unknown or uncertain primary.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.